{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T00:04:19Z","timestamp":1705190659206},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.molmed.2004.04.003","type":"journal-article","created":{"date-parts":[[2004,5,13]],"date-time":"2004-05-13T13:44:36Z","timestamp":1084455876000},"page":"269-274","source":"Crossref","is-referenced-by-count":12,"title":["Methods for targeting biologicals to specific disease sites"],"prefix":"10.1016","volume":"10","author":[{"given":"Ahuva","family":"Nissim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yarunnessa","family":"Gofur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Vessillier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gill","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuti","family":"Chernajovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2004.04.003_BIB1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2004.04.003_BIB2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1182\/blood.V65.6.1349.bloodjournal6561349","article-title":"A clinical trial of anti-idiotype therapy for B cell malignancy","volume":"65","author":"Meeker","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2004.04.003_BIB3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00007890-198112000-00018","article-title":"Treatment of acute renal allograft rejection with OKT3 monoclonal antibody","volume":"32","author":"Cosimi","year":"1981","journal-title":"Transplantation"},{"key":"10.1016\/j.molmed.2004.04.003_BIB4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","article-title":"Improving the efficacy of antibody-based cancer therapies","volume":"1","author":"Carter","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.molmed.2004.04.003_BIB5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4049\/jimmunol.135.2.1530","article-title":"Human immune response to multiple injections of murine monoclonal IgG","volume":"135","author":"Shawler","year":"1985","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/312643a0","article-title":"Production of functional chimaeric mouse\/human antibody","volume":"312","author":"Boulianne","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2004.04.003_BIB7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/321522a0","article-title":"Replacing the complementarity-determining regions in a human antibody with those from a mouse","volume":"321","author":"Jones","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2004.04.003_BIB8","first-page":"52","article-title":"The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies","volume":"26","author":"Dyer","year":"1999","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB9","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.molmed.2004.04.003_BIB10","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"Suppl 1","key":"10.1016\/j.molmed.2004.04.003_BIB11","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1023\/A:1011172125897","article-title":"Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data","volume":"12","author":"Eiermann","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molmed.2004.04.003_BIB13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1359-6446(03)02955-6","article-title":"Anti-cytokine Ab immune therapy: present status and perspectives","volume":"9","author":"Zagury","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.molmed.2004.04.003_BIB14","first-page":"89","article-title":"Tumour targeting with immunocytokines. A novel approach for cancer therapy","volume":"10","author":"Pertl","year":"1998","journal-title":"Minerva Biotec."},{"key":"10.1016\/j.molmed.2004.04.003_BIB15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0952-7915(99)00017-5","article-title":"A new era for radiolabeled antibodies in cancer?","volume":"11","author":"DeNardo","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB16","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0952-7915(99)00012-6","article-title":"Monoclonal antibody drug conjugates in the treatment of cancer","volume":"11","author":"Trail","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB17","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin anti-Tac(Fv)\u2013PE38 (LMB-2) in patients with haematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/362255a0","article-title":"Germ-line transmission and expression of a human-derived yeast artificial chromosome","volume":"362","author":"Jakobovits","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2004.04.003_BIB19","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/j.1460-2075.1994.tb06626.x","article-title":"Isolation of high affinity human antibodies directly from large synthetic repertoires","volume":"13","author":"Griffiths","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.molmed.2004.04.003_BIB20","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/j.1460-2075.1994.tb06308.x","article-title":"Antibody fragments from a \u2018single pot\u2019 phage display library as immunochemical reagents","volume":"13","author":"Nissim","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.molmed.2004.04.003_BIB21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tibtech.2003.08.007","article-title":"Domain antibodies: proteins for therapy","volume":"21","author":"Holt","year":"2003","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0958-1669(99)80016-0","article-title":"Phage-display technology: finding a needle in a vast molecular haystack","volume":"10","author":"Rodi","year":"1999","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB23","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1073\/pnas.94.10.4937","article-title":"In vitro selection and evolution of functional proteins by using ribosome display","volume":"94","author":"Hanes","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2004.04.003_BIB24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nbt0697-553","article-title":"Yeast surface display for screening combinatorial polypeptide libraries","volume":"15","author":"Boder","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/380364a0","article-title":"Organ targeting in vivo using phage display peptide libraries","volume":"380","author":"Pasqualini","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2004.04.003_BIB26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1126\/science.279.5349.377","article-title":"Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model","volume":"279","author":"Arap","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.molmed.2004.04.003_BIB27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm0202-121","article-title":"Steps toward mapping the human vasculature by phage display","volume":"8","author":"Arap","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2004.04.003_BIB28","series-title":"Pharmacology of cytokines","author":"Mantovani","year":"2000"},{"key":"10.1016\/j.molmed.2004.04.003_BIB29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01741084","article-title":"Interleukin-2 in cancer treatment: disappointing or (still) promising? A review","volume":"36","author":"Maas","year":"1993","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2004.04.003_BIB30","doi-asserted-by":"crossref","unstructured":"Rosenberg, S.A. et al. (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474\u2013484, discussion 484\u2013485.","DOI":"10.1097\/00000658-198910000-00008"},{"key":"10.1016\/j.molmed.2004.04.003_BIB31","first-page":"5234","article-title":"Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant IL-2","volume":"50","author":"Hank","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2004.04.003_BIB32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000187289","article-title":"Renal toxicity mediated by continuous infusion of recombinant IL-2","volume":"64","author":"Ponce","year":"1993","journal-title":"Nephron"},{"key":"10.1016\/j.molmed.2004.04.003_BIB33","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","article-title":"Interleukin-2 toxicity","volume":"9","author":"Siegel","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB34","first-page":"7037","article-title":"Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose IL-2","volume":"49","author":"Maas","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2004.04.003_BIB35","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/1097-0142(19881215)62:12<2482::AID-CNCR2820621205>3.0.CO;2-9","article-title":"Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of IL-2 injected perilymphatically","volume":"62","author":"Cortesina","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.molmed.2004.04.003_BIB36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jnci\/89.1.21","article-title":"Gene therapy for cancer: what have we done and where are we going?","volume":"89","author":"Roth","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.molmed.2004.04.003_BIB37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00666167","article-title":"Breast cancer gene therapy: transgenic immunotherapy","volume":"31","author":"Su","year":"1994","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.molmed.2004.04.003_BIB38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0163-7258(98)00033-3","article-title":"Immunocytokines: a promising approach to cancer immunotherapy","volume":"80","author":"Lode","year":"1998","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2004.04.003_BIB39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00002371-199401000-00004","article-title":"Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus IL-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro","volume":"15","author":"Hank","year":"1994","journal-title":"J. Immunother."},{"key":"10.1016\/j.molmed.2004.04.003_BIB40","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4049\/jimmunol.139.3.971","article-title":"Treatment of a murine B cell lymphoma with monoclonal antibodies and IL-2","volume":"139","author":"Berinstein","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB41","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/0952-7915(93)90129-G","article-title":"Monoclonal antibodies in cancer therapy","volume":"5","author":"Riethmuller","year":"1993","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB42","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.4049\/jimmunol.157.7.3165","article-title":"In vivo properties of an IgG3-IL-2 fusion protein. A general strategy for immune potentiation","volume":"157","author":"Harvill","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1021\/bc00021a008","article-title":"Biological activity and in vivo clearance of antitumor antibody\/cytokine fusion proteins","volume":"4","author":"Gillies","year":"1993","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.molmed.2004.04.003_BIB44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/hyb.1991.10.347","article-title":"Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody","volume":"10","author":"Gillies","year":"1991","journal-title":"Hybridoma"},{"key":"10.1016\/j.molmed.2004.04.003_BIB45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/362755a0","article-title":"Idiotype\/GM-CSF fusion protein as a vaccine for B-cell lymphoma","volume":"362","author":"Tao","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2004.04.003_BIB46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/152581699320153","article-title":"Construction, expression, and characterization of anticarcinoma sFv fused to IL-2 or GM-CSF","volume":"8","author":"Zhao","year":"1999","journal-title":"J. Hematother. Stem Cell Res."},{"key":"10.1016\/j.molmed.2004.04.003_BIB47","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.4049\/jimmunol.160.12.6195","article-title":"Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases","volume":"160","author":"Gillies","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-1759(00)00345-8","article-title":"Antibody-cytokine fusion proteins for the therapy of cancer","volume":"248","author":"Penichet","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.molmed.2004.04.003_BIB49","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1073\/pnas.89.4.1428","article-title":"Antibody-targeted IL-2 stimulates T-cell killing of autologous tumor cells","volume":"89","author":"Gillies","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2004.04.003_BIB50","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1084\/jem.183.5.2361","article-title":"T cell-mediated eradication of murine metastatic melanoma induced by targeted IL-2 therapy","volume":"183","author":"Becker","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2004.04.003_BIB51","series-title":"Antibody fusion proteins","first-page":"15","article-title":"Fab fusion proteins: immunoligands","author":"Penichet","year":"1999"},{"key":"10.1016\/j.molmed.2004.04.003_BIB52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0065-230X(08)60740-X","article-title":"Extracellular matrix-associated TGF\u03b2: role in cancer cell growth and invasion","volume":"75","author":"Taipale","year":"1998","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.molmed.2004.04.003_BIB53","doi-asserted-by":"crossref","first-page":"25378","DOI":"10.1016\/S0021-9258(19)74051-4","article-title":"Release of TGF\u03b2-1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin","volume":"267","author":"Taipale","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2004.04.003_BIB54","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1172\/JCI114932","article-title":"Recombinant latent TGF-\u03b21has a longer plasma half life in rats than active TGF-\u03b21, and a different tissue distribution","volume":"86","author":"Wakefield","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2004.04.003_BIB55","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nbt888","article-title":"Targeting cytokines to sites of inflammation","volume":"21","author":"Adams","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB56","first-page":"1059","article-title":"Improved pharmacokinetic properties of a polyethylene glycol-modified form of IFN-\u03b2-1-a with preserved in vitro bioactivity","volume":"297","author":"Pepinsky","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2004.04.003_BIB57","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00262-002-0302-6","article-title":"Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer","volume":"51","author":"Gillies","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.molmed.2004.04.003_BIB58","first-page":"701","article-title":"Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases","volume":"52","author":"DeClerck","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.molmed.2004.04.003_BIB59","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1358836X9800300309","article-title":"The interface of atherosclerosis and thrombosis: basic mechanisms","volume":"3","author":"Libby","year":"1998","journal-title":"Vasc. Med."},{"key":"10.1016\/j.molmed.2004.04.003_BIB60","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2990.1997.tb01315.x","article-title":"Differential MMP expression in cases of multiple sclerosis and stroke","volume":"23","author":"Anthony","year":"1997","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.molmed.2004.04.003_BIB61","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/121.12.2327","article-title":"MMP-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis","volume":"121","author":"Leppert","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.molmed.2004.04.003_BIB62","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1063-4584(97)80045-3","article-title":"Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis","volume":"5","author":"Singer","year":"1997","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.molmed.2004.04.003_BIB63","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0016-5085(99)70339-2","article-title":"MMP levels are elevated in inflammatory bowel disease","volume":"117","author":"Baugh","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2004.04.003_BIB64","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.4049\/jimmunol.161.7.3729","article-title":"A RANTES-antibody fusion protein retains antigen specificity and chemokine function","volume":"161","author":"Challita-Eid","year":"1998","journal-title":"J. Immunol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491404001005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491404001005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T11:28:20Z","timestamp":1705145300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491404001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S1471491404001005"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2004.04.003","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}